Literature DB >> 17135805

ADCS Prevention Instrument Project: overview and initial results.

Steven H Ferris1, Paul S Aisen, Jeffrey Cummings, Douglas Galasko, David P Salmon, Lon Schneider, Mary Sano, Peter J Whitehouse, Steven Edland, Leon J Thal.   

Abstract

One objective of the Alzheimer's Disease Cooperative Study (ADCS) is to develop new or improved instruments and assessment methods for evaluating treatment efficacy in Alzheimer disease (AD) clinical trials. The ADCS Instrument Committee has previously helped to define the state of the art in assessment for AD and Mild Cognitive Impairment clinical trials. We are now entering an exciting era of primary prevention trials to evaluate promising treatments that may delay disease onset and there is a need to develop appropriate instruments for these trials. The ADCS instrument committee has undertaken a project to develop instruments for prevention studies that assess domains known to be important in AD. Prevention trials are long and require large numbers of subjects, making them costly and requiring a high burden of participation for subjects. The current study focused on developing instruments that can be completed at home and in the clinic. The instruments are being evaluated in a cohort of nondemented elderly participating in a 4-year longitudinal study that simulates the design of a primary prevention trial. This report describes the design, baseline characteristics, and some longitudinal outcomes of the study cohort through the completion of the first 2 years of follow-up. We also describe the assessment domains to be measured with our new experimental instruments. This study recruited 644 subjects, 75 years of age and older. Participation in a "book club" that provided free books of interest to elders was offered as a recruitment incentive. Approximately 23% had some mild cognitive symptoms consistent with a Clinical Dementia Rating of 0.5. All subjects received a standardized in-clinic evaluation at baseline, which is repeated annually for 4 years to identify cases suspected of developing dementia and to measure longitudinal change on established clinical assessments. Subjects completed a set of self-administered experimental instruments at home or in the clinic designed to assess cognitive function and behavior, global change, activities of daily living, quality of life, and resource use. An additional "mail-in cognitive function questionnaire" was obtained separately by mail, 1 month before the other assessments. To evaluate the feasibility, efficiency, and validity of the home-based instruments in comparison with acquiring the same information during a clinic visit, subjects were randomized to 1 of 2 conditions in which the baseline and annual follow-up assessments are completed either at home ("home group") or at the study site during their clinic visits ("clinic group"). This initial report describes the ongoing 4-year longitudinal study and provides baseline results, which confirm the feasibility of obtaining home-based clinical information via mail or telephone. Initial results for the experimental instruments and for the book club are reported in separate accompanying articles.

Entities:  

Mesh:

Year:  2006        PMID: 17135805     DOI: 10.1097/01.wad.0000213870.40300.21

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  29 in total

Review 1.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.

Authors:  Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.

Authors:  Zaven S Khachaturian; Deborah Barnes; Richard Einstein; Sterling Johnson; Virginia Lee; Allen Roses; Mark A Sager; William R Shankle; Peter J Snyder; Ronald C Petersen; Gerard Schellenberg; John Trojanowski; Paul Aisen; Marilyn S Albert; John C S Breitner; Neil Buckholtz; Maria Carrillo; Steven Ferris; Barry D Greenberg; Michael Grundman; Ara S Khachaturian; Lewis H Kuller; Oscar L Lopez; Paul Maruff; Richard C Mohs; Marcelle Morrison-Bogorad; Creighton Phelps; Eric Reiman; Marwan Sabbagh; Mary Sano; Lon S Schneider; Eric Siemers; Pierre Tariot; Jacques Touchon; Bruno Vellas; Lisa J Bain
Journal:  Alzheimers Dement       Date:  2010-03       Impact factor: 21.566

Review 3.  Functional Disability in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Cutter A Lindbergh; Rodney K Dishman; L Stephen Miller
Journal:  Neuropsychol Rev       Date:  2016-07-08       Impact factor: 7.444

4.  Sample size determination for a matched-pairs study with incomplete data using exact approach.

Authors:  Guogen Shan; Charles Bernick; Sarah Banks
Journal:  Br J Math Stat Psychol       Date:  2017-06-30       Impact factor: 3.380

5.  Hearing loss and cognition in the Baltimore Longitudinal Study of Aging.

Authors:  Frank R Lin; Luigi Ferrucci; E Jeffrey Metter; Yang An; Alan B Zonderman; Susan M Resnick
Journal:  Neuropsychology       Date:  2011-11       Impact factor: 3.295

6.  Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.

Authors:  Christopher M Callahan; Wanzhu Tu; Timothy E Stump; Daniel O Clark; Kathleen T Unroe; Hugh C Hendrie
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

7.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.

Authors:  Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman
Journal:  N Engl J Med       Date:  2009-07-16       Impact factor: 91.245

8.  Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease.

Authors:  Ellen Grober; Charles B Hall; Richard B Lipton; Alan B Zonderman; Susan M Resnick; Claudia Kawas
Journal:  J Int Neuropsychol Soc       Date:  2008-03       Impact factor: 2.892

9.  The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults.

Authors:  Clara Li; Judith Neugroschl; Xiaodong Luo; Carolyn Zhu; Paul Aisen; Steven Ferris; Mary Sano
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  Developing dementia prevention trials: baseline report of the Home-Based Assessment study.

Authors:  Mary Sano; Susan Egelko; Michael Donohue; Steven Ferris; Jeffrey Kaye; Tamara L Hayes; James C Mundt; Chung-Kai Sun; Silvia Paparello; Paul S Aisen
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.